United States
Print page content Print
Increase text size Decrease text size
Text Size

Resvac® 4/Somubac®

Bovine Rhinotracheitis-Virus Diarrhea- Parainfluenza 3 virus Respiratory Syncytial Virus Vaccine - Haemophilus Somnus Bacterin

RESVAC 4/SOMUBAC

Resvac 4/Somubac is for vaccination of healthy, nonpregnant cattle as an aid in preventing infectious bovine rhinotracheitis caused by infectious bovine rhinotracheitis (IBR) virus, bovine viral diarrhea caused by bovine viral diarrhea (BVD) Type 1 virus, and disease caused by PI3 (parainfluenza3 virus) virus, bovine respiratory syncytial virus (BRSV) and Haemophilus somnus.

Resvac 4/Somubac consists of a standardized combination of freeze-dried, attenuated strains of IBR, BVD Type 1, PI3, and BRSV viruses propagated in stable cell lines; accompanied by liquid, inactivated, standardized bacterin diluent.

Somubac is prepared from selected strains of Haemophilus somnus which are grown serum-free in an environmentally controlled fermentation system and inactivated in such a manner as to maintain their immunogenic integrity. The bacterin is adjuvanted with aluminum hydroxide.

Collapse All
  • Uses

    Aids in the prevention of diseases caused by infectious bovine rhinotracheitis (IBR) virus, bovine viral diarrhea (BVD) Type 1 virus, PI3 (parainfluenza3 virus) virus, bovine respiratory syncytial virus (BRSV) and Histophilus somni (Haemophilus somnus).

    Key Features

    • Helps provide protection against four of the most common bovine viral respiratory diseases, plus H. somni.
    • Intramuscular (IM) dose is 2mL.  Administer two doses two to four weeks apart.
    • Annual revaccination with a single dose is recommended.

    Safety and Efficacy

    Studies in cattle show Resvac 4/Somubac to be safe and free from untoward reactions. This product was field tested in thousands of cattle by practicing veterinarians. No undesirable effects attributable to the product were noted.

    Vaccination/challenge studies in cattle showed each fraction contained in Resvac 4 to be effective as an aid in the prevention of disease caused by IBR, BVD Type 1, PI3 and BRSV viruses. Cattle vaccinated with Somubac were protected against challenge with a highly virulent strain  of Haemophilus somnus. Antigen interference studies in cattle show each fraction of the Resvac 4/Somubac combination to be compatible.

  • Packaging

    10- and 50-dose vials.

    Directions

    1. General directions:  Vaccination of healthy, nonpregnant cattle is recommended. Aseptically rehydrate the freeze-dried vaccine with the liquid bacterin provided, shake well, and administer 2mL intramuscularly. In accordance with Beef Quality Assurance guidelines, this product should be administered in the muscular region of the neck.
    2. Primary vaccination:  Healthy, nonpregnant cattle three months of age or older should receive two doses administered two to four weeks apart.
    3. Revaccination: Annual revaccination with a single dose is recommended. Calves with maternal antibodies may not develop or maintain satisfactory levels of immunity; therefore, calves vaccinated before six months of age should be revaccinated at six months of age or at weaning.
    4. Good animal husbandry and herd health management practices should be employed.
  • Precautions

    1. Do not use in pregnant cows (abortions can result) or in calves nursing pregnant cows.
    2. Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
    3. Use entire contents when first opened.
    4. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
    5. Burn containers and all unused contents.
    6. Do not vaccinate within 21 days before slaughter.
    7. Contains polymyxin B and neomycin as preservatives.
    8. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
    9. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.